Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 26, 2007

Albany Molecular Research Leads European Cancer Program

  • Albany Molecular Research (AMRI) launched a project to discover and develop novel anticancer agents through a collaboration of 10 life sciences companies and academic centers. The CancerGrid Project is a three-year multidisciplinary research program funded by the European Commission.

    "This innovative project utilizes grid-based computing technology for the automated design of chemical libraries with the goal of discovering potential cancer treatments," says Michael Guaciaro, Ph.D., president and managing director of AMRI’s European operations.

    Grid computing uses multiple computational resources in a parallel manner, allowing researchers to tap into a network of interconnected workstations that can process large amounts of data in less time. This project is also expected to produce and validate a technology for in silico design of chemical libraries and models that predict toxicity and target specificity.

    In addition to IMRI’s site in Budapest, Hungary, the consortium includes Inte:Ligand, Tallinn University of Technology, University of Helsinki, GKI Economic Research, Computer and Automation Research Institute, DAC Srl and University of Bari, University Pompeu Fabra, and Hebrew University of Jerusalem Hebrew University of Jerusalem.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »